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ABSTRACT
Objective: This article presents the methodology and
results of the pharmacoeconomic analysis of the Magnex
Against Standard COmbination Therapy study comparing
cefoperazone-sulbactam (Magnex) versus ceftazidime+
amikacin+metronidazole, in the treatment of intra-
abdominal infections.
Methods: This prospective, open label, phase IV study was
conducted at 17 study sites in India and randomized subjects
to receive either cefoperazone-sulbactam or the combination.
Pharmacoeconomic analysis was included as a secondary
objective and conducted in the clinical efﬁcacy-evaluable
(CEE) and the successfully treated patients. All comparisons
between treatment groups were conducted using analysis of
variance (ANOVA) or Wilcoxon Two-Sample tests. All costs
were reported as Indian Rupee (INR) and actual unit costs
collected in 2006 were used for the analyses [1 USD ~ 40
INR; 1 Euro ~ 56 INR].
Results: In the CEE and the successfully treated subset of
patients, the average cost of treatment was numerically lower
in the cefoperazone-sulbactam arm (not statistically signiﬁ-
cant). The analyses found that the cost-effectiveness ratio
(CER) for cefoperazone-sulbactam was INR 17,640.53
and that for the comparator group was INR 22,075.16.
Additionally, the incremental CER results showed that the
cost of treatment was INR 21,505.59 lower per additional
successfully treated patient in the cefoperazone-sulbactam
group.
Conclusions: The present study was the ﬁrst of its kind to be
conducted in the “price sensitive” Indian health-care setting.
Though study was not powered for the difference in average
cost of treatments, there was a trend favoring cefoperazone
sulbactam. The ﬁndings from this study should encourage
further conduct of similar analyses and increase the knowl-
edge regarding pharmacoeconomics in India.
Keywords: cefoperazone-sulbactam, cost-effectiveness, intra-
abdominal infections, pharmacoeconomics.
Introduction
Indian Health-Care Scenario
The state of India’s health care is growing at a rapid
pace. Health-care cost as a percentage of the gross
domestic product (GDP) is 5.1% and is designated as
a priority for the government. Health-care spending is
expected to increase from $21 billion in 2005 to $45
billion in 2012. Public spending is anticipated to grow
from the present amount of 0.9% of the GDP to 2%
of the GDP by 2009. India carries a mixed disease
burden—age-old infectious diseases; reemergence of
diseases like tuberculosis and malaria; dreaded dis-
eases like cancer and AIDS; lifestyle diseases like car-
diovascular (CV), diabetes, and depression. Disease
burdens are projected to rise rapidly with 60% of the
global CV burden by 2020 and 73 million diabetic
patients by 2025. The changing disease proﬁle there-
fore calls for more advanced and innovative therapies
[1].
A substantial share of the Indian population
(i.e., about 200 million middle class with disposable
incomes) are increasingly able to afford to pay for
medicines. “Self-pay” or out-of-pocket payment cur-
rently accounts for 75% of all health-care spending
(the central or state governments pay for 19%, other
public spending accounts for 3%, and other private
spending accounts for the remaining 3%) and will
remain the key payment mode. Approximately 15% of
the population has some form of prepayment coverage
but the growth in health insurance coverage is ham-
pered by regulatory provisions. Medications comprise
approximately 20% of total health-care spending and
the per capita expenditure on medicines, currently at
$5.60, is likely to increase substantially with improved
literacy rates, increased access to medical information,
and the rise in income levels [2]. The evolving status of
India’s health care makes it important to perform
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research studies/cost-efﬁcacy analysis (CEA) to justify
the “value proposition” from the patients “perspec-
tive” as well from the perspective of various other
stakeholders, e.g., regulators, pricing authority, insur-
ers and doctors, which can bring about the improve-
ment of the health-care system in the country.
Magnex Against Standard COmbination Therapy
(MASCOT) Rationale and Design
Intraabdominal infections are often polymicrobial and
include aerobic as well as anaerobic bacteria. Anti-
biotics used to treat intraabdominal infections should
target organisms such as Enterobacteriaceae and
Bacteroides fragilis, which are commonly known to
cause these infections [3]. Combinations of a third-
generation cephalosporin, an aminoglycoside, and
metronidazole are often used to treat intraabdominal
infections in surgical settings. An alternative treatment
for these infections is a beta lactam-beta lactamase
inhibitor combination such as cefoperazone-sulbactam.
The safety and efﬁcacy of cefoperazone-sulbactam
was compared to ceftazidime plus amikacin and
metronidazole (comparator treatment) in a random-
ized, open-label, multicenter (17 sites across India),
phase IV study for the treatment of intraabdominal
infections. At the end of treatment visit, a clinical
outcome evaluation was performed and categorized as
success, deﬁned by complete resolution of baseline
signs and symptoms; improvement, deﬁned as resolu-
tion of some, but not all baseline symptoms and
no further systemic antimicrobials administered; or
failure, which was deﬁned by the need for additional
systemic antimicrobial therapy, the need for more than
one surgical procedure or death 48 h after initiating
therapy. Those participants who achieved clinical
success or improvement at the end of the treatment
visit were evaluated after 30 days and categorized as
having either continued resolution, deﬁned by the con-
tinued absence of, or minimal, signs and symptoms
not requiring further therapy, or relapse, deﬁned as a
return or worsening of signs and symptoms requiring
therapy. Subjects who could not be categorized into
any of the outcomes were regarded as indeterminate.
The primary efﬁcacy variable was the proportion of
efﬁcacy-evaluable subjects having a clinical outcome of
continued resolution at the Test of Cure (TOC)/30-day
follow-up visit.
In total, 92% of cefoperazone-sulbactam-treated
subjects had continued resolution at the follow-up
visit compared with 82% in the comparator group
(P = 0.015). The difference between treatments was
10.1% (95% CI 2.1–18.1%). The lower limit of the
95% CI was higher than the predeﬁned noninferiority
limit of >-12.5%; thus noninferiority was demon-
strated. Superiority of cefoperazone sulbactam was
demonstrated for both the clinical efﬁcacy-evaluable
(CEE) population and the modiﬁed intent to treat
(MITT) population (lower limit of 95% CI for the
difference between treatments >0%). In the MITT
analysis, 89.3% of subjects treated with cefoperazone
sulbactam had continued resolution of their clinical
signs and symptoms at the 30-day follow-up visit com-
pared with 79.2% in the comparator group.
In addition, cefoperazone-sulbactam was found to
have a better safety proﬁle compared with the com-
parator with a lower number of treatment-related
adverse events (AEs) and discontinuations due to
treatment-related AEs. The details of the efﬁcacy
and safety of cefoperazone-sulbactam are presented
separately [4].
Objectives
The primary objective of the MASCOT study con-
ducted in India was to evaluate the efﬁcacy of
cefoperazone-sulbactam in comparison with ceftazi-
dime plus amikacin and metronidazole for intra-
abdominal infections. The secondary objectives of the
MASCOT study included the assessment of the safety
proﬁle of cefoperazone-sulbactam and the analysis of
relevant pharmacoeconomic data for cefoperazone-
sulbactam. During the past 15 years, a substantial
international interest has developed in the economic
evaluation of health-care and medical technologies [5].
The present study evaluating the pharmacoeconomic
data of cefoperazone-sulbactam versus a comparator
was the ﬁrst of its kind to be conducted in India. It was
also the ﬁrst study that compared a mono-therapy with
a three-drug combination in the Indian health-care
setting. The objectives of this article are to present the
methodology and results of the economic evaluations
conducted as part of the MASCOT study.
Methods
MASCOT was planned as a noninferiority study. Non-
inferiority trials are intended to show that the effect of
a new treatment is not worse than that of an active
control by more than a speciﬁed margin. Subjects with
intraabdominal infections were stratiﬁed based on age
and baseline Acute Physiology, Age, and Chronic
Health Evaluation II scores and randomized to receive
either cefoperazone-sulbactam or the combination
of ceftazidime, amikacin, and metronidazole. Subjects
were treated with the study medication intravenously
(IV) for a minimum of ﬁve days and not more than
14 days. Subjects were assessed daily during the treat-
ment period and the end of treatment visit occurred
within 12 h of the last dose of study medication.
Details of the trial design and methodology will be
presented in detail as a separate article.
Comparison of pharmacoeconomic data for
cefoperazone-sulbactam versus the comparator was
one of the secondary objectives of the MASCOT study.
The following costs were analyzed: the cost of medi-
cations; hospitalization charges; cost of interventions
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done for source control (e.g., surgical interventions,
laparoscopy, laparotomy, etc.); and cost of consulta-
tions, referrals, and investigations. The case report
form (CRF) used in the study captured the units for
each cost item (the different cost items are presented in
Appendix A). Both costs for the primary source inter-
vention or surgery and complications which resulted in
secondary interventions or surgeries were considered
in the cost analysis. But, the costs of concomitant
medications or switches have not been included in this
cost analysis because many generics are available with
varying costs. Hence, if a patient failed the study drug
and was started on another therapy, that cost (of new
medication) was not included in this study. Neverthe-
less, if the patient was transferred to an intensive care
unit or required reintervention, then that cost was
included.
A standardized unit cost (Indian Rupee or INR
value) was assigned to the data collected in the CRF.
Actual unit costs for each cost item from across sites
participating in the study were collected for both
government/municipal and private hospitals in 2006
and were used to compute the total cost of treatment
of patients at their hospitals. This cost was then used
to calculate the average total cost in the two therapeu-
tic arms. All costs are reported as INR [1 USD ~ 40
INR; 1 Euro ~ 56 INR].
A CEA was conducted as part of this study. The
average cost-effectiveness ratio (CER) was calculated
for each treatment alternative, and the incremental
CER (ICER) was calculated The ICER is deﬁned as a
ratio of the difference in costs between two alternatives
to the difference in the effectiveness between the alter-
natives and is calculated as follows:
ICER Cost Effect
Cost Cost
E
New Alternative Comparator
= ( ) ( )
= −( )
Δ Δ
ffect EffectNew Alternative Comparator−( )
where “cost” and “effect” are deﬁned consistently
with those used to compute the average CER.
In this study speciﬁcally, the ICER was calculated as
follows:
ICER Total cost of treatment A
Total cost of treatment B
Success r
= −(
)
ate of treatment A
Success rate of treatment B
−(
)
The overall objective of the pharmacoeconomic
analyses was to determine whether there was any dif-
ference in the average cost of treatment per patient
between the two treatment arms (i.e., cefoperazone-
sulbactam vs. comparator). To meet this objective,
analyses were conducted in the CEE patients. All com-
parisons between treatment groups were conducted
using analysis of variance (ANOVA) or Wilcoxon
Two-Sample tests.
Results
Demographics
At baseline, 306 patients were randomized to treatment
in the MASCOT study with 154 patients in the
cefoperazone-sulbactam arm and 152 patients in the
comparator arm. In both treatment arms, a majority
of patients were male (cefoperazone-sulbactam: 119,
77.3%; comparator: 113, 74.3%). The mean age of
patients in the cefoperazone-sulbactam group was
36.4 years (SD = 15.4) and that in the comparator
group was 35.7 years (SD = 16.3). Most of the patients
in both treatment arms were between the ages of
18–44 years (cefoperazone-sulbactam: 87, 56.5%;
comparator: 93, 61.2%). Themeanweights and heights
in both treatment armswere similar. Details of the study
demographics at baseline are presented in Table 1.
Cost Comparisons
Of the cost items, the biggest drivers of cost were
surgeries, hospitalization cost, disposable syringe sets,
IV ﬂuid packs, IV sets, and arterial blood gas analysis.
Although the average costs for these cost items were
lower in the cefoperazone-sulbactam arm than in the
comparator arm, there were no signiﬁcant differences
between the two arms (Table 2).
MITT population. There were 152 subjects in each
arm. Although the average cost of treatment per patient
in the cefoperazone-sulbactam armwas lower than that
of the comparator arm, there was no signiﬁcant
difference between the treatment arms (cefoperazone-
sulbactam: INR 17,111.05 (SD = 11,661.27); com-
parator: INR 18,446.57 (SD = 14,732.5); P = 0.3816).
The difference in the average cost of treatment per
patient between the two arms was approximately INR
1336. Similarly, the average cost of treatment per
patient in the cefoperazone-sulbactam group was lower
in both the government/municipal hospitals and private
hospitals but there were no signiﬁcant differences
between the groups in either the government/municipal
or private hospital settings (for government/municipal
hospitals: cefoperazone-sulbactam: INR 11,682.35
(SD = 7231.67); comparator: INR 13,221.91
(SD = 8998.31); P = 0.5698) (for private hospitals:
Table 1 Baseline demographics
Characteristic
Cefoperazone-sulbactam
(n = 154)
Comparator
(n = 152)
Male, n (%) 119 (77.3) 113 (74.3)
Mean age, years (SD) 36.4 (15.4) 35.7 (16.3)
<18 (n) 15 18
18–44 (n) 87 93
45–64 (n) 42 28
65 (n) 10 13
Mean weight, kg (SD) 55.4 (11.7) 54.1 (11.3)
Mean height, cm (SD) 159.6 (10.7) 159.6 (10.8)
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cefoperazone-sulbactam: INR 29,669.18 [SD =
6792.84]; comparator: INR 35,457.40 [SD =
17,854.97]; P = 0.1648). The differences in average
cost of treatment per patient between the two treatment
arms in the government/municipal hospitals and private
hospitals were INR 811.4 and INR 5788, respectively
(Table 3). Additionally, it was found that the average
cost of treatment per patient in the government/
municipal hospitals was signiﬁcantly lower than in the
private hospitals (P < 0.0001).
There was no signiﬁcant difference in the average
drug cost of treatment per patient between the
two treatment arms (cefoperazone-sulbactam: INR
5412.98 [SD = 3170.26]; comparator: INR 5869.91
[SD = 3035.35]; P = 0.2003). The difference in average
drug cost per patient between the two treatment arms
was approximately INR 457 (Table 4). Additionally,
the average length of hospitalizations was very similar
between the cefoperazone-sulbactam and the com-
parator groups (cefoperazone-sulbactam: 10.52 days
[SD = 5.29]; comparator: 10.49 days [SD = 6.19]).
Nevertheless, duration of hospitalization in the
“special care unit/ICU” was signiﬁcantly longer in the
comparator arm (P = 0.03) (Table 5).
CEE subset. At the end of the study, there were 134
clinically evaluable patients in the cefoperazone-
sulbactam arm and 132 patients in the comparator
arm. CEE population is a subset of ITT, which was
evaluated for efﬁcacy. Subjects excluded from the CEE
analysis population were all excluded due to protocol
deviations like prohibited concomitant antimicrobial
medication use, insufﬁcient therapy, evidence of malig-
nant disease, intestinal tuberculosis or amoebic pathol-
ogy; lack of post baseline clinical assessments, death
within 48 h of study therapy, patients did not meet
eligibility criteria, suspected source of intra-abdominal
infection was not conﬁrmed.
Cost-Effectiveness Analyses
Of the 134 patients treated with cefoperazone-
sulbactam, 125 patients were treated successfully (i.e.,
CEE subjects who presented themselves with contin-
ued resolution at the 30-day follow-up visit/TOC visit)
and of the 132 patients treated with comparator,
108 patients were successfully treated. Therefore, the
cefoperazone-sulbactam treatment arm had a higher
success rate (91.79%) compared to the comparator
treatment arm (81.82%). The CER or the average cost
per successfully treated patient for cefoperazone-
sulbactam was INR 17,640.53 and that for the com-
parator group was INR 22,075.16 [CEE population].
The CER calculated for MITT population was
19,704.11 for cefoperazone-sulbactam and 26,333.43
for the comparator. Therefore, the average cost per
successfully treated patient was INR 6629.32 lower in
the cefoperazone-sulbactam group than in the com-
parator group (Table 6).
Table 2 Biggest cost drivers in the two treatment arms
Cost item
Average costs for
cefoperazone-
sulbactam (INR)
Average costs
for comparator
(INR)
Cost difference
(cefoperazone-
sulbactam-comparator) P-value
Surgeries 3454.80 4037.10 -582.30 0.45
Hospitalization cost (general ward and special care unit) 1114.60 1393.60 -279.00 0.33
Disposable syringe sets 811.87 1146.50 -334.60 0.34
Intravenous ﬂuid packs 754.82 944.33 -189.50 0.29
Intravenous sets 441.46 631.13 -189.70 0.15
Arterial blood gas analysis 381.04 487.38 -106.30 0.12
INR, Indian Rupee.
Table 3 Average treatment cost per patient—modiﬁed intent to treat population
Cefoperazone-sulbactam Comparator P-value 95% CI
Overall 0.3816 (-4,335, 1,663.5)
N 154 152
Average cost/patient INR 17,111.05 INR 18,446.57
SD 11,661.27 14,732.5
Government/municipal hospital 0.5698 (-3,621, 1,998.4)
N 128 130
Average cost/patient INR 11,682.35 INR 13,221.91
SD 7,231.67 8,998.31
Private hospital 0.1648 (-1,3686, 2,109.7)
N 24 22
Average cost/patient INR 29,669.18 INR 35,457.40
SD 6,792.84 17,854.97
INR, Indian Rupee.
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Discussion
MASCOT was the ﬁrst prospective study with phar-
macoeconomic endpoints in India. Results demon-
strated that cefoperazone-sulbactam was superior to
the comparator used in the study (i.e., combination of
ceftazidime, amikacin, and metronidazole) and that it
also had a better safety proﬁle. In addition to its clini-
cal advantage in treating intraabdominal infections,
the MASCOT study found that in the CEE popula-
tion of patients, the average cost of treatment per
patient overall, as well as in both the government/
municipal and private hospital settings was lower in
the cefoperazone-sulbactam group than the compara-
tor group (but no signiﬁcant difference was found in
any of these cases). As expected, the average cost of
treatment per patient in both the arms was signiﬁ-
cantly lower in the government/municipal hospitals
than in the private hospitals. Additionally, the study
also found that there was no signiﬁcant difference
in the average drug cost of treatment per patient
between the two treatment arms and that the average
length of hospitalizations was very similar between
the two arms. The average drug cost per patient for
the successfully treated population was lower in the
cefoperazone-sulbactam group, although there was no
signiﬁcant difference between the two treatment arms.
Additionally, the ICER results showed that the cost of
treating a patient with cefoperazone-sulbactam was
over INR 21,000 less per additional successfully
treated patient.
Clinical trials are often considered artiﬁcial treat-
ment environments, and may not provide all the eco-
nomic information needed by decision-makers. Trial
populations may not commonly reﬂect patient groups
treated in clinical practice, and the time horizon for
trials often may not reﬂect the duration of impact of
the intervention [2] One of the limitations of the pha-
macoeconomic evaluation in the present study was the
lack of inclusion of costs of alternative therapy in event
of failure of study medication. Nevertheless, we did
capture the cost of complications that might have
occurred in these patients. The primary efﬁcacy vari-
able was the proportion of efﬁcacy-evaluable subjects
having a clinical outcome of continued resolution at
the 30-day follow-up or TOC visit. Another limitation
was that we did not capture any costs that might have
incurred during the 30-day interval. Nevertheless, in
retrospect, this can be justiﬁed on the account that the
there were no additional failures during this period
and the success rates for both the arms remained con-
sistent (additional costs unlikely). Another limitation is
that the study uses a surrogate end point. Future
studies in this premise should also include collection of
utility weights from amongst the patient population to
build a CER using QALY methods.
The MASCOT study was not only the ﬁrst study
comparing a monotherapy versus a three-drug combi-
nation in the Indian setting, it was also the ﬁrst study
to conduct a pharmacoeconomic analysis to show the
overall cost advantages of the treatment options within
this health-care environment. In India, where the
current health-care system requires patients to “self-
pay” for their treatments, and therefore prescribers are
sensitive to prices, it is important for a treatment to
show a pharmacoeconomic advantage. Cefoperazone-
sulbactam had a lower drug cost per patient and a
lower overall average cost of treatment per patient
when compared to the comparator. Though this differ-
Table 4 Average drug cost per patient—modiﬁed intent to treat population
Cefoperazone-
sulbactam (n = 154)
Comparator
(n = 152) P-value 95% CI
Average cost/patient INR 5412.98 INR 5869.91 0.2003 (-1,157, 243.62)
SD 3170.26 3035.35
INR, Indian Rupee.
Table 5 Length of hospitalizations—modiﬁed intent to treat
population
Cefoperazone-sulbactam
Mean (SD)
Comparator
Mean (SD)
Hospitalizations 10.52 days (5.29) 10.49 days (6.19)
n = 151 n = 148
Special care unit 0.47 days (1.23) 1.04 days (2.74)*
n = 130 n = 131
Special nursing care 0.37 days (1.18) 0.52 day (1.91)
n = 128 n = 124
*P = 0.03.
Table 6 Results of cost-effectiveness analyses
Cefoperazone-
sulbactam Comparator
Number of MITT patients 154 152
Number of clinically evaluable
(CEE) patients
134 132
Number of patients
successfully treated
125 108
Success rate for CEE
population
91.79%* 81.82%
Success rate for MITT
population
81.2%† 71.2%†
Average CER (calculated for
MITT population)
INR 19,704.11 INR 26,333.43
*Odds ratio 2.52; 95% CI 1.18–5.38; P = 0.015.
†95% CI 2.0% to 18.3%; P = 0.015.
CEE, clinical efﬁcacy-evaluable; CER, cost-effectiveness ratio; INR, Indian Rupee;MITT,
modiﬁed intent to treat.
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ence was not signiﬁcant (the study was not powered
for this end point), it reﬂects a trend in costs.
With emerging privatized health care in India, the
results will have considerable impact on how hospital
groups may decide to purchase medications for
patients. It will be important to consider not only the
drug acquisition costs when making a treatment deci-
sion, but to consider the lower overall treatment cost
when treating patients with intraabdominal infections.
The results from this study demonstrated the impor-
tance of pharmacoeconomics and will likely inﬂuence
the methodology of future treatment comparison trials
conducted in India.
Conclusions
This is the ﬁrst prospective study with pharmacoeco-
nomic endpoints in India. As the science is still in its
nascent stage, more pharmacoeconomic work will be
necessary to establish sound methodologies in the
Indian health-care context.
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Appendix A Costs Items
1. Medication Cost
a. Drug costs including details of the drug and
number of days of treatment
i. Study medication
ii. Concomitant medications (drugs started
postrandomization)
iii. Posttreatment medications (drugs started at
the end of treatment (EOT) for ongoing
symptoms. This will include additional/
alternative antimicrobials for treatment
failures)
b. Cost of consumables
i. IV ﬂuids
ii. IV sets
iii. Disposable syringes and needles
2. Hospitalization charges including the number of
days of hospitalization (including special care
units)
a. Bed charges
b. Nursing charges
3. Cost of intervention for source control including
the type and number of interventions
a. Primary procedure for source control
b. Additional procedure, if performed
4. Cost of investigations including the type and
number of investigations (investigations performed
at the screening visit was not included as part of the
pharmacoeconomic analysis)
a. Clinical laboratory tests
b. Radiological investigations
c. Microbiological tests
5. Consultation charges (except treating surgeon)
including the number of referrals made by the treat-
ing surgeon
a. Physicians
b. Physiotherapists
c. Occupational therapists
d. Intensive care specialists
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